Action on Hearing Loss Logo
    Total results:
    Search
      Total results:

      Another step forward for gene therapy to treat hearing loss

      Researchers from Harvard Medical School in the US have recently used gene therapy to restore hearing in mice with a particular type of Usher syndrome. Carina Santos, our Translational Research Manager, tells us more about the work, and what it means for using gene therapy to treat hearing loss in people in the future.

      By: Carina Santos | 14 June 2017

      Genes are the master regulators of the characteristics that make us human, from the colour of our eyes to the number of toes we have in each foot, and our hearing is no exception!

      Over half of the cases of hearing loss in children worldwide are due to errors in genes called mutations. In fact, hearing loss acquired during ageing can also be influenced by our genetic make-up. Scientists around the world are working hard to develop gene therapies to correct the mutations that cause hearing loss. Two recent advances made by researchers at Harvard Medical School in the US have brought the prospect of gene therapies for hearing loss closer.

      Delivering genes to the cochlea (inner ear)

      The cochlea is the “hearing” part of the ear, where the sensory hair cells are located. These cells are responsible for translating sound into electrical signals that are sent to the brain, allowing us to hear. So, genetic mutations that affect the way these cells develop or work are likely to cause hearing loss. Scientists working on gene therapy to correct gene mutations in hair cells face the substantial challenge of how to deliver corrected genes to the large number of sensory hair cells in the cochlea, which is hard to access, as it is hidden behind the mastoid bone in our skull, the hardest bone in the body.

      The research, published this month in the scientific journal Nature Biotechnology, presents a new and highly efficient method of delivering corrected genes to 80-90% of sensory hair cells, using a new viral vector called Anc80L65. A viral vector is a harmless virus that scientists engineer to infect specific cells and deliver genes into them. Anc80L65 surpasses existing vectors because its high efficiency allows delivery of genes to different types of hair cells (called inner and outer hair cells), which have complementary and essential roles in the hearing process, as well as vestibular hair cells, which control balance and spatial orientation.

      How gene therapy restored hearing and balance in a mouse model

      Usher syndrome is a genetic disorder that causes profound deafness, blindness and balance disorders. It is responsible for 3-6% of childhood deafness. In a specific type of Usher syndrome, called type 1c, a gene called USH1C is defective, which results in hair cells failing to develop correctly, showing disorganised hair bundles (the hair-like structures on top of the cells that sense sound, and that give hair cells their name), and then dying. In this study, the researchers used mice which have the same mutation in their version of the USH1C gene, which is called Ush1c (naming conventions for genes mean that mouse genes are in lower case, while human genes are capitalised).

      By introducing a corrected version of the Ush1c gene into the inner ear of newborn mice, using the Anc80L65 vector, the researchers were able to restore the correct organization of the hair bundles and improve hearing in the mice by over a thousand-fold, relative to other existing inner ear gene therapy approaches. Along with hearing, balance was also restored in these mice. Although it’s still early days, gene therapy shows promise as a treatment to restore hearing and studies like these are helping to speed up access to these therapies by people.

      What’s next?

      The researchers are now focussed on perfecting the Anc80L65 vector, to limit the delivery of genes to hair cells only. Moreover, although the therapy showed the highest efficiency when used in newborn mice, the best therapeutic window for humans is still to be determined. Unlike in mice, human hearing is fully developed before birth and researchers need to assess if gene therapy would have to be given pre-natally, which would be a significant challenge, or if it will work if administered after birth.

      Find out more

      We depend on your donations so we can fund the best hearing and tinnitus research around the world. Donate today and help us continue our vital work into hearing treatments, so that people can live life to the full again.

      This research was published in the journal Nature Biotechnology.

      Full references:

      Pan B, Askew C, Galvin A, Heman-Ackah S, Asai Y, Indzhykulian AA, Jodelka FM, Hastings ML, Lentz JJ, Vandenberghe LH, Holt JR and Geleoc GS. Gene therapy restores auditory and vestibular function in a mouse model of Usher syndrome type 1c. Nat Biotechnol. 2017 Mar; 35(3):264-272.

      Landegger LD, Pan B, Askew C, Wassmer SJ, Gluck SD, Galvin A, Taylor R, Forge A, Stankovic KM, Holt JR, Vandenberghe LH. A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear. Nat Biotechnol. 2017 Mar; 35(3):280-284.

      You can find out more about our students, and the research we’re funding, in our biomedical research section.

      If you’re interested in finding out more about our research, sign up to receive our Soundbite e-newsletter. It’s a monthly email, filled with the latest news about hearing and tinnitus research.

      Recent Posts

      EE partnership brings unbeatable packages

      For the first time ever, selected mobile phones with EE Pay As You Go plans, tailored for people who are deaf or have hearing loss, are available from Action on Hearing Loss.

      By: Brian Burns
      17 October 2018

      REGAIN update on the progress so far and a further opportunity for people with hearing loss to take part in the trial

      A team of researchers and clinicians at UCL’s Ear Institute and the Royal National Throat Nose and Ear Hospital are delighted to announce that the REGAIN trial is approaching its first anniversary and are continuing to recruit people with hearing loss to participate in a ground breaking clinical trial to test the safety and efficacy of a new drug that aims to treat sensorineural hearing loss. The criteria for eligibility to participate in the trial has recently been broadened to include participants with hearing loss of up to 20 years duration (see below for further information).

      By: REGAIN
      16 October 2018

      Preventing hearing loss: the search for treatments

      Medicines like aminoglycoside antibiotics or cisplatin are used to combat life-threatening infections and cancer, respectively, but their use may come at the price of someone’s hearing. Several treatments to prevent the loss of hearing caused by these medicines are currently being developed. Our Translational Research Manager, Dr Carina Santos, tells us more.

      By: Dr Carina Santos
      12 October 2018

      Shining a light on the cochlea

      We fund research across the globe into treatments for hearing loss and tinnitus. One of our newest projects, at the Bionics Institute in Australia, is investigating if we can improve how well cochlear implants work using light.

      By: Dr Tracey Pollard
      11 October 2018

      More like this

      We're really proud of everyone who's a part of Action on Hearing Loss, and hope you'll feel inspired to become a part of our community.​

      We campaign for changes that make life better for people who are confronting deafness, tinnitus and hearing loss.

      Our ears are our organs of hearing and balance. They have three parts: the outer, middle and inner ear.